AGT
AGT encodes angiotensinogen, the sole precursor of all angiotensin peptides in the renin-angiotensin-aldosterone system. It is primarily synthesized by the liver and is a key determinant of systemic blood pressure and vascular health.
Key Takeaways
- •AGT encodes angiotensinogen, the indispensable sole precursor for all angiotensin peptides.
- •Circulating AGT levels are a primary rate-limiting factor for systemic blood pressure control.
- •Common genetic variants (like M235T) drive higher AGT levels and lifelong risk of essential hypertension.
- •Visceral fat acts as an extra-hepatic source of AGT, linking obesity directly to high blood pressure.
Basic Information
- Gene Symbol
- AGT
- Full Name
- Angiotensinogen
- Also Known As
- SERPINA8Angiotensinogen
- Location
- 1q42.2
- Protein Type
- Plasma Protein (Serpin-like)
- Protein Family
- Serpin Family
Related Isoforms
Key SNPs
One of the most robustly validated hypertension variants. The T allele is linked to higher baseline AGT levels and increased risk of elevated blood pressure.
Frequently studied variant that influences AGT expression and modifies cardiovascular risk profiles.
Overview
The AGT gene encodes angiotensinogen, a 452-amino acid alpha-2-globulin that serves as the unique raw material for the renin-angiotensin-aldosterone system (RAAS). It is produced constitutively by the liver and released into the circulation. AGT is biologically inactive until it is cleaved by the enzyme renin to produce the inactive decapeptide Angiotensin I, which is subsequently converted to the active octapeptide Angiotensin II by ACE.
Because AGT is the only source of angiotensin peptides, the concentration of AGT in the blood is a major rate-limiting step in the activation of the entire RAAS axis. Even modest increases in hepatic or adipose AGT production can lead to chronic elevations in systemic blood pressure and accelerated vascular remodeling.
Conceptual Model
A simplified mental model for the pathway:
AGT is the pool of potential energy; the more AGT available, the higher the capacity for the body to raise blood pressure.
Core Health Impacts
- • Blood pressure set-point: Circulating AGT levels dictate the baseline tone of the RAAS system.
- • Fluid homeostasis: Provides the substrate required for aldosterone-mediated sodium retention.
- • Vascular remodeling: Elevated AGT levels drive the production of Ang II, which causes vessel wall thickening.
- • Metabolic-BP link: Adipose-derived AGT mediates the link between weight gain and hypertension.
Upstream Regulators
Glucocorticoids Activator
Cortisol stimulates hepatic synthesis of AGT, contributing to stress-induced hypertension.
Estrogens Activator
Potently increase AGT production, explaining the BP rise in pregnancy or oral contraceptive use.
Thyroid Hormones Activator
Increase hepatic AGT transcription to maintain metabolic-vascular balance.
Inflammation (IL-6) Activator
Acute phase cytokines upregulate AGT, linking inflammation to increased cardiovascular tension.
Downstream Targets
Angiotensin I Activates
The immediate decapeptide product of renin-mediated AGT cleavage.
Angiotensin II Activates
The ultimate effector; produced downstream of AGT to drive vasoconstriction.
Aldosterone Activates
Release is stimulated by AGT-derived Ang II to increase salt retention.
NADPH Oxidase Activates
Activated by Ang II to increase oxidative stress in the vascular lining.
Role in Aging
AGT levels are a key determinant of "Vascular Age." Chronic over-supply of the AGT precursor leads to a hyper-responsive RAAS system that accelerates arterial stiffening over decades.
Vascular Stiffening
Lifelong elevation of AGT (as seen in M235T carriers) promotes chronic low-grade Ang II activity, driving collagen deposition in artery walls.
Adipose Expansion
With age and visceral fat accumulation, the adipose-to-hepatic AGT ratio shifts, making BP regulation more dependent on fat mass.
Kidney Decline
High systemic AGT levels increase intra-glomerular pressure, accelerating the age-related decline in filtration capacity (eGFR).
Hypertension Progression
Genetic variants in AGT create a "field defect" where blood pressure rises more steeply with age compared to protective genotypes.
Disorders & Diseases
Essential Hypertension
AGT variants are major genetic contributors to primary high blood pressure in the general population.
Preeclampsia
Excessive AGT production, often driven by high estrogens or placental distress, is a hallmark of pregnancy-induced hypertension.
Renal Tubular Dysgenesis
Rare recessive mutations in AGT prevent kidney development, leading to severe fetal skull defects and death.
Metabolic Syndrome
Over-production of AGT by visceral fat is a primary mechanism linking obesity to cardiovascular disease.
Interventions
Supplements
Known to repress the RAAS system; deficiency is associated with higher AGT-cleavage activity.
May modestly lower systemic RAAS activity, mildly offsetting high AGT levels.
Directly antagonizes the sodium-retaining effects of the AGT-Renin-Aldo axis.
Lifestyle
Crucial for reducing extra-hepatic AGT production from adipose tissue depots.
Reduces the homeostatic demand for the RAAS signaling that begins with AGT.
Improves endothelial health and lowers the sympathetic drive that triggers AGT cleavage.
Medicines
The only medicine that directly blocks the first step of the cascade: the cleavage of AGT itself.
Block the downstream conversion of AGT-derived Ang I into the active Ang II.
Block the receptors that respond to the peptides produced from AGT.
Lab Tests & Biomarkers
Activity Markers
Directly measures the precursor concentration; elevated in hypertension and pregnancy.
Measures the rate at which AGT is being actively converted into Angiotensin I.
Hormonal Interactions
Renin Primary Cleaver
The rate-limiting enzyme that cuts AGT to start the blood pressure cascade.
Estrogen Transcriptional Driver
Strongly upregulates hepatic AGT expression, linking reproductive health to vascular tone.
Aldosterone Downstream Effector
The end-stage hormone that retains salt in response to the AGT cascade.
Deep Dive
Network Diagrams
The AGT / RAAS Cascade
Source Origins of AGT
The Molecular Reservoir: Kinetics of AGT
Angiotensinogen is unique among RAAS components because it is a “high-abundance” precursor. While hormones like insulin or adrenalin are produced only when needed, the liver maintains a constant, massive reservoir of AGT in the blood.
The kinetics of the RAAS pathway are determined by the encounter between AGT and the enzyme renin. Because the concentration of AGT in human plasma is close to the Michaelis constant (Km) of the renin reaction, any change in the amount of AGT—whether due to genetics (M235T variant) or hormones (estrogen)—immediately and directly translates into a change in the rate of Angiotensin II production.
The Adipose-Vascular Link
For decades, the liver was thought to be the only source of AGT. However, it is now known that white adipose tissue (fat) is a significant producer of its own local angiotensinogen.
In states of obesity, the expanding visceral fat mass pumps out extra AGT into the portal circulation. This additional supply “overloads” the system, driving a state of chronic RAAS over-activation. This explains one of the most common clinical observations in medicine: why losing weight is so effective at lowering blood pressure. By shrinking the fat, you are effectively reducing the body’s total “dose” of the AGT precursor.
Pregnancy and the AGT Surge
Pregnancy represents a major physiological stress test for the AGT system. High levels of estrogen during pregnancy potently stimulate the liver to increase AGT production.
In a healthy pregnancy, the body compensates for this increased precursor by reducing the sensitivity of blood vessels to Angiotensin II. However, in women with genetic predispositions (like the M235T variant), the AGT surge can overwhelm these compensatory mechanisms, leading to the rapid development of hypertension and preeclampsia.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The seminal discovery linking the AGT M235T variant to the risk of essential hypertension.
One of the first clinical observations that circulating AGT levels directly correlate with blood pressure levels.